Mallinckrodt Hit With Securities Suit After $100M FTC Deal
Just days after it reached a $100 million deal with the Federal Trade Commission and several states to end allegations it had snapped up a monopoly on infant seizure drug Acthar,...To view the full article, register now.
Already a subscriber? Click here to view full article